CH391L/S12/GeneandGenomeSynthesis

From OpenWetWare

< CH391L/S12
Revision as of 10:15, 12 March 2012 by Jeffrey E. Barrick (Talk | contribs)
(diff) ←Older revision | Current revision (diff) | Newer revision→ (diff)
Jump to: navigation, search


Contents

Gene and Genome Synthesis

Introduction

Gene synthesis, or artificial gene synthesis, refers to the process of creating a nucleic acid template for a gene in vitro, without the requirement of a preexisting DNA template. Soon after the elucidation of the genetic code and the description of the central dogma of molecular biology, there arose a need to synthesize genes de novo in order to study their biological function both in the test tube and in model organisms. Chemical synthesis of DNA has grown from an expensive and time-consuming process into a viable commercial industry capable of high-throughput manufacture of almost any scale of custom DNA molecules in almost any context. This allows species-specific gene optimization, creation of genes from rare or dangerous sources, and combinatorial assembly of any DNA sequence that can be chemically synthesized, even including non-traditional bases. The most advanced applications of gene synthesis have been applied to the recent creation of completely synthetic minimal genomes in prokaryotes.

Despite nearly four decades of progress in gene synthesis technologies, most DNA sequences used in modern molecular biology are assembled in part or in whole from naturally occurring templates. However this limits the scope and applications to previously existing genes and the results of large-scale genomic surveys of novel genes from nature. Modern gene synthesis relies heavily on advancements in chemical DNA oligonucleotide synthesis, with the primary challenges being scale, cost, fidelity and the eventual assembly of complete gene products.

A directory of commercial gene synthesis providers can be found at Genespace.

History of Gene Synthesis

Gene synthesis predates the invention of restriction enzymes and molecular cloning techniques by several years. The first gene to be completely synthesized in vitro was a 77-nt alanine transfer RNA by the laboratory of Har Gobind Khorana in 1972 [1]. This was the result of nearly five years of work and resulted in a DNA template without promoter or transcriptional control sequences. The first peptide- and protein-producing synthetic genes were created in 1977 and 1979, respectively [2, 3]. Steady advancement has led to recent synthesis of complete gene clusters tens of thousands of nucleotides in length, and ultimately a bacterial genome approximately 1.2 million bases in length.

Oligonucleotide Synthesis

Regardless of the length of the eventual product, synthetic DNA constructs are built from some combination of short DNA oligonucleotides. These oligonucleotides are later assembled into a complementary DNA duplex, amplified and inserted into their final genetic context.

Oligonucleotides are chemically synthesized from DNA phosphoramidite monomers. Briefly, activated phosphoramidite monomers are added in the 3' to 5' direction using a cyclical activation and blocking chemistry to obtain a DNA polymer linked by phosphodiester bonds.

Image:CH391L_S12_Phosphoramidite.png

Chemical synthesis is currently limited to oligonucleotides of about 200 nt in length.

Summary of Methods

Ligation-Based Methods

In ligation-mediated assembly, the synthetic gene or DNA fragment of interest is broken up into individual overlapping DNA oligonucleotides that cover both strands of the eventual DNA duplex. In contrast to PCR-based methods of gene synthesis, there are no gaps introduced in either strand during design, but rather the oligonucleotides completely reconstitute the eventual DNA target.

The oligonucleotides are chemically synthesized and phosphorylated at their 5' ends using purified kinase in an in vitro reaction. After complementary oligo fragments are annealed using using thermal cycling, purified DNA ligase is added to the reaction in order to splice together the 3' OH and 5' phosphate gaps on each backbone.

PCR-based Methods

PCR-based gene assembly strategies are similar to ligation-mediated assembly, except that oligonucleotide precursors are linked together leaving gaps that must be filled in by DNA polymerase. In the most common method, polymerase cycling assembly (PCA), DNA oligonucleotides are designed to be part of either the top or bottom of the final DNA duplex. Cycles of annealing and polymerase extension result in a growing DNA duplex built from smaller oligonucleotide fragments. A final round of PCR is done with constant primers that amplify the complete desired gene product. Initial oligo linkage is done for 20-30 cycles and full-length PCR is carried out for 20-30 additional cycles.

Oligos must be designed carefully to have similar melting temperatures and be free of interfering secondary structures (high GC content, hairpins, etc.)

Image:CH391L_S12_PCA.jpg

Solid-Phase Synthesis

An alternative gene synthesis technique using solid-phase synthesis of a DNA duplex has been created by several companies, including Blue Heron. In these methods, DNA oligonucleotides are synthesized as in other techniques, they are annealed into complementary short duplexes without overhanging ends, and these duplexes are chemically ligated on a solid phase such as a liquid chromatography column. The complete synthetic DNA duplex is then eluted and used for downstream processes, such as cloning or gene expression.

Multiplex/Microchip Synthesis

DNA oligonucleotides have become a commodity and the price per base has been steadily dropping. But there is still great expense involved in large-scale gene synthesis. For a several kilobase gene fragment, oligo cost alone can still exceed $1,000. To over come this hurdle, multiplex parallel gene synthesis technologies are under development, including inkjet DNA printers, photolithography and electrochemical parallel synthesis.

Microfluidic microchips are a common multiplexing solution. In the method of Tian et al. [4], oligonucleotides are synthesized while coupled to a microchip at their 3' end. The overall process is similar to traditional oligo synthesis, except that individual wells are photoactivated before addition of the next base onto the 5' end. After chemical cleavage of the complete oligo from the microchip, they are hybridized and purified using complementary "quality assurance" oligos bound to magnetic beads. This method eliminates oligos that have either incorporated extra bases or undergone deletions. Final yield from each synthesis well is only around 5 fmol of oligo, which is not sufficient for downstream applications. A final amplification step using common PCR primers to all oligos increases yields up to a million-fold. Oligos can then be assembled by overlap PCR-based methods such as polymerase assembly multiplexing, or PAM. This method has resulted in the synthesis, amplification and expression of a 14.5 kb, 21-gene 30S ribosomal protein operon from E. coli.

Minimizing Errors

One major roadblock remaining in synthetic gene synthesis is overcoming natural error rates in DNA synthesis chemistry. Phosphoramidite oligo synthesis currently has an error rate of 1 in ~160. This results in a high enough error rate in assembled genes that screening and sequencing are major cost bottlenecks, as is the repair or re-synthesis of mutated genes. While the development of cheap and high-throughput sequencing technologies will streamline the screening process, oligo synthesis error rates must also be reduced.

Currently, oligo pools are often screened against complementary reference libraries that can be reused. Oligos that do not completely base-pair with their designed sequence are either washed away in purification steps or are cleaved by DNA mismatch repair proteins due to their imperfect base-pairing. This has currently decreased error rates to 1 in 106, on the order of error rates in DNA polymerases.

Genome Synthesis

J. Craig Venter's team at JCVI have worked to carry gene synthesis to its most advanced level - the creation of a completely synthetic genome. Initially, the JCVI team synthesized a 582,970-base pair "minimized" genome of Mycoplasma genitalium using a stepwise assembly [5]. The genome was divided into 24 cassettes of about 24 kb each which were synthesized by commercial manufacturers. These overlapping cassettes were enzymatically stitched together into bacterial artificial chromosomes, which were attached in a stepwise fashion using a combination of restriction digestion and in vitro recombination. At the point where the molecules were "quarter genomes", they were transformed into yeast where in vivo recombination machinery assembled the full M. genitalium chromosome. This was only proof of synthesis, however, and not of a synthetic genome useful for supporting a living organism.

In 2010, the JCVI team reported the creation of a bacterium controlled by a fully synthetic genome[6]. The 1.08 mega-base pair genome of Mycoplasma mycoides was synthesized and transplanted into a M. capricolum recipient cell to create synthetic bacterium nicknamed "Synthia". The genome was divided into 1,078 1-kb cassettes, which were synthesized by Blue Heron. These cassettes were assembled in yeast using in vivo homologous recombination using a three-step hierarchy that built fragments of ~10,000 bp, ~100,000 bp and finally the complete 1.08 mega-bp genome. These were then isolated carefully from contaminating yeast DNA and transplanted into the recipient bacteria. A selectable marker placed in the synthetic genome demonstrated that bacteria that grew after transplantation were controlled by the synthetic genome. The same team demonstrated that a semi-synthetic genome could be assembled and transplanted using a combination of natural and synthetic DNA.

In 2011, a group from Johns Hopkins reported the first partially synthetic eukaryotic genome. They edited approximately 1% of the Saccharaomyces cerevisiae genome to eliminate introns, repetitive sequence and retrotransposons, replaced all TAG stop codons with TAA, and introduced recombigenic LoxPSym sites to aid in future large-scale manipulations of the genome [7].

Overall error rates in synthetic genome assembly were controlled by careful cassette synthesis and verification, as well as relying on high-fidelity in vivo recombination methods for hierarchical construction. Even low error rates can have huge effects, though. One single base deletion in the genome was in an essential gene, dnaA, and delayed progress for many weeks. Isolation, growth and manipulation of mega-base pair DNA molecules either in vivo or in vitro is a difficult roadblock as well.

Gibson Assembly

Final assembly of large double-stranded DNA products into kilobase and megabase functional molecules, free of errors and with minimal cost remains a process bottleneck for gene and genome synthesis. In vitro recombination methods have been successfully used to assemble large DNA molecules on the order of tens of kilobases, but this method remains prone to errors and requires considerable homology be engineered into assembly fragments.

In 2009, Daniel Gibson of J. Craig Venter's group reported a method for assembling hundreds of kilobases of DNA sequence using an isothermal enzymatic setup known today as "Gibson Assembly"[8]. Sub-fragments of the eventual assembly product are obtained as blunt-ended double-stranded DNA molecules several kilobases in length. They share several hundred bases of homology at their adjacent termini. T5 DNA Exonuclease chews back the double-stranded DNA molecule to reveal 3' single-stranded overhangs. Being heat-liable, T5 exonuclease is inactivated after several minutes at the reaction temperature. A mixture of thermostable ligase and DNA polymerase repair and assemble the individual fragments into larger molecules. This method has been used to assemble nonfunctional DNA molecules up to 900 kilobases in length, as well as the complete 16.3 kilobase mouse mitochondrial genome [9]. The size limit of molecules that can be assembled in this manner is currently limited to the cost of design and screening the final assembly products and the hundreds of kilobases of DNA that must be sequenced.

Links of Interest

References

  1. Khorana HG, Agarwal KL, Büchi H, Caruthers MH, Gupta NK, Kleppe K, Kumar A, Otsuka E, RajBhandary UL, Van de Sande JH, Sgaramella V, Terao T, Weber H, and Yamada T. . pmid:4571075. PubMed HubMed [Khorana1972]
  2. Itakura K, Hirose T, Crea R, Riggs AD, Heyneker HL, Bolivar F, and Boyer HW. . pmid:412251. PubMed HubMed [Itakura1977]
  3. Goeddel DV, Kleid DG, Bolivar F, Heyneker HL, Yansura DG, Crea R, Hirose T, Kraszewski A, Itakura K, and Riggs AD. . pmid:85300. PubMed HubMed [Goeddell1979]
  4. Tian J, Gong H, Sheng N, Zhou X, Gulari E, Gao X, and Church G. . pmid:15616567. PubMed HubMed [Tian2004]
  5. Gibson DG, Benders GA, Andrews-Pfannkoch C, Denisova EA, Baden-Tillson H, Zaveri J, Stockwell TB, Brownley A, Thomas DW, Algire MA, Merryman C, Young L, Noskov VN, Glass JI, Venter JC, Hutchison CA 3rd, and Smith HO. . pmid:18218864. PubMed HubMed [Gibson2008]
  6. Gibson DG, Glass JI, Lartigue C, Noskov VN, Chuang RY, Algire MA, Benders GA, Montague MG, Ma L, Moodie MM, Merryman C, Vashee S, Krishnakumar R, Assad-Garcia N, Andrews-Pfannkoch C, Denisova EA, Young L, Qi ZQ, Segall-Shapiro TH, Calvey CH, Parmar PP, Hutchison CA 3rd, Smith HO, and Venter JC. . pmid:20488990. PubMed HubMed [Gibson2010]
  7. Dymond JS, Richardson SM, Coombes CE, Babatz T, Muller H, Annaluru N, Blake WJ, Schwerzmann JW, Dai J, Lindstrom DL, Boeke AC, Gottschling DE, Chandrasegaran S, Bader JS, and Boeke JD. . pmid:21918511. PubMed HubMed [Dymond2011]
  8. Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA 3rd, and Smith HO. . pmid:19363495. PubMed HubMed [Gibson2009]
  9. Gibson DG, Smith HO, Hutchison CA 3rd, Venter JC, and Merryman C. . pmid:20935651. PubMed HubMed [Gibson2010b]
All Medline abstracts: PubMed HubMed
Personal tools